Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbbVie Inc. stock logo
ABBV
AbbVie
$189.50
-0.7%
$187.12
$163.52
$218.66
$336.25B0.486.24 million shs3.70 million shs
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$133.70
-0.3%
$133.11
$99.71
$141.23
$232.61B0.736.14 million shs3.11 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$779.60
+0.0%
$777.35
$677.09
$972.53
$739.51B0.43.66 million shs1.44 million shs
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$80.95
-1.7%
$79.22
$73.31
$129.93
$203.27B0.3913.22 million shs7.73 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$25.45
+0.5%
$23.62
$20.92
$31.54
$144.72B0.5841.52 million shs27.04 million shs
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbbVie Inc. stock logo
ABBV
AbbVie
+0.45%+2.77%+2.14%-5.23%+14.95%
Abbott Laboratories stock logo
ABT
Abbott Laboratories
-1.57%-2.46%+0.43%+1.91%+29.92%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
+0.31%-1.70%+4.33%-1.23%-14.09%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
+0.75%+3.29%+8.05%-4.59%-35.52%
Pfizer Inc. stock logo
PFE
Pfizer
+1.16%+4.24%+8.00%+4.22%-9.02%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AbbVie Inc. stock logo
ABBV
AbbVie
4.9144 of 5 stars
3.45.03.33.92.81.71.3
Abbott Laboratories stock logo
ABT
Abbott Laboratories
4.8981 of 5 stars
2.43.04.24.52.92.52.5
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
4.9889 of 5 stars
4.44.03.34.02.91.71.9
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
4.9971 of 5 stars
3.23.05.03.93.02.53.8
Pfizer Inc. stock logo
PFE
Pfizer
4.9763 of 5 stars
3.23.04.24.32.81.73.1
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AbbVie Inc. stock logo
ABBV
AbbVie
2.81
Moderate Buy$211.2911.50% Upside
Abbott Laboratories stock logo
ABT
Abbott Laboratories
2.76
Moderate Buy$142.616.67% Upside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.75
Moderate Buy$1,011.6129.76% Upside
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
2.43
Hold$109.1934.88% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.45
Hold$28.5512.18% Upside

Current Analyst Ratings Breakdown

Latest MRK, PFE, ABT, LLY, and ABBV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/20/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$936.00
6/16/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
6/16/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageMarket Perform$143.00
6/11/2025
AbbVie Inc. stock logo
ABBV
AbbVie
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold$205.00
6/9/2025
AbbVie Inc. stock logo
ABBV
AbbVie
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold$204.00
6/5/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Erste Group Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
5/29/2025
Pfizer Inc. stock logo
PFE
Pfizer
Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold$28.00 ➝ $25.00
5/23/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
5/21/2025
Pfizer Inc. stock logo
PFE
Pfizer
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy$32.00 ➝ $33.00
5/20/2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Cautious
5/19/2025
Pfizer Inc. stock logo
PFE
Pfizer
HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy$27.00 ➝ $26.00
(Data available from 7/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AbbVie Inc. stock logo
ABBV
AbbVie
$56.33B5.94$14.90 per share12.72$1.90 per share99.74
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$41.95B5.54$6.46 per share20.70$27.62 per share4.84
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$45.04B16.40$14.30 per share54.51$15.03 per share51.87
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$64.17B3.17$9.37 per share8.64$18.33 per share4.42
Pfizer Inc. stock logo
PFE
Pfizer
$63.63B2.27$4.43 per share5.74$15.62 per share1.63
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AbbVie Inc. stock logo
ABBV
AbbVie
$4.28B$2.3581.0013.561.267.31%412.03%13.11%7/24/2025 (Estimated)
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$13.40B$7.7117.3423.332.5931.89%19.01%10.82%7/17/2025 (Estimated)
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$10.59B$12.2963.4925.051.1322.67%85.51%15.74%8/7/2025 (Estimated)
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$17.12B$6.8711.788.180.8527.27%43.23%17.11%7/29/2025 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$8.03B$1.3818.458.400.9112.62%20.33%8.53%8/5/2025 (Estimated)

Latest MRK, PFE, ABT, LLY, and ABBV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/29/2025Q2 2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$2.03N/AN/AN/A$15.92 billionN/A
7/24/2025Q2 2025
AbbVie Inc. stock logo
ABBV
AbbVie
$3.24N/AN/AN/A$14.93 billionN/A
7/17/2025Q2 2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$1.25N/AN/AN/A$11.01 billionN/A
5/1/2025Q1 2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$4.64$3.34-$1.30$3.06$12.77 billion$12.73 billion
4/29/2025Q1 2025
Pfizer Inc. stock logo
PFE
Pfizer
$0.67$0.92+$0.25$0.52$14.43 billion$13.72 billion
4/25/2025Q1 2025
AbbVie Inc. stock logo
ABBV
AbbVie
$2.40$2.46+$0.06$0.72$12.91 billion$13.34 billion
4/24/2025Q1 2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$2.16$2.22+$0.06$2.01$15.59 billion$15.53 billion
4/16/2025Q1 2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$1.07$1.09+$0.02$0.76$10.38 billion$10.36 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AbbVie Inc. stock logo
ABBV
AbbVie
$6.563.46%N/A279.15%53 Years
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$2.361.77%N/A30.61%54 Years
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.000.77%N/A48.82%11 Years
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$3.244.00%N/A47.16%14 Years
Pfizer Inc. stock logo
PFE
Pfizer
$1.726.76%N/A124.64%16 Years

Latest MRK, PFE, ABT, LLY, and ABBV Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/23/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
quarterly$1.500.78%8/15/20258/15/20259/10/2025
6/25/2025
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.437.08%7/25/20257/25/20259/2/2025
6/20/2025
AbbVie Inc. stock logo
ABBV
AbbVie
quarterly$1.643.54%7/15/20257/15/20258/15/2025
6/13/2025
Abbott Laboratories stock logo
ABT
Abbott Laboratories
quarterly$0.591.73%7/15/20257/15/20258/15/2025
5/27/2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
quarterly$0.814.18%6/16/20256/16/20257/8/2025
4/23/2025
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.437.69%5/9/20255/9/20256/13/2025
5/5/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
quarterly$1.500.73%5/16/20255/16/20256/10/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AbbVie Inc. stock logo
ABBV
AbbVie
44.14
0.76
0.64
Abbott Laboratories stock logo
ABT
Abbott Laboratories
0.26
1.78
1.27
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.18
1.37
1.06
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.69
1.41
1.16
Pfizer Inc. stock logo
PFE
Pfizer
0.64
1.26
0.96

Institutional Ownership

CompanyInstitutional Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
70.23%
Abbott Laboratories stock logo
ABT
Abbott Laboratories
75.18%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
76.07%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%

Insider Ownership

CompanyInsider Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
0.25%
Abbott Laboratories stock logo
ABT
Abbott Laboratories
0.46%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.13%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.13%
Pfizer Inc. stock logo
PFE
Pfizer
0.06%
CompanyEmployeesShares OutstandingFree FloatOptionable
AbbVie Inc. stock logo
ABBV
AbbVie
55,0001.77 billion1.76 billionOptionable
Abbott Laboratories stock logo
ABT
Abbott Laboratories
114,0001.74 billion1.73 billionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
47,000947.74 million946.50 millionOptionable
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
75,0002.51 billion2.51 billionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
81,0005.69 billion5.68 billionOptionable

Recent News About These Companies

Pfizer: Options Activity Speaks Bullish
Pfizer: Options Activity Speaks Bullish
Is Pfizer Stock a Yield Trap?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
AbbVie stock logo

AbbVie NYSE:ABBV

$189.50 -1.25 (-0.66%)
As of 03:47 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Abbott Laboratories stock logo

Abbott Laboratories NYSE:ABT

$133.70 -0.42 (-0.31%)
As of 03:34 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$779.60 +0.32 (+0.04%)
As of 03:48 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Merck & Co., Inc. stock logo

Merck & Co., Inc. NYSE:MRK

$80.95 -1.44 (-1.75%)
As of 03:47 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Pfizer stock logo

Pfizer NYSE:PFE

$25.45 +0.13 (+0.51%)
As of 03:47 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.